Flow chart of study patients

128 Enrolled patients
68 children (6-14 y)
60 adults (15-60 y)

63 assigned to ARPQ
34 children
29 adults

2 non-\textit{P. falciparum} monoinfection at admission to study determined by PCR
3 protocol violation
2 lost to follow-up

55 (87%; 30 children, 25 adults) completed 42 days follow-up or had a recurrence of malaria

65 assigned to ASAQ
34 children
31 adults

2 did not complete treatment
1 non-\textit{P. falciparum} monoinfection at admission to study determined by PCR
1 protocol violation
2 lost to follow-up

59 (91%, 31 children, 28 adults) completed 42 days follow-up or had a recurrence of malaria

\textbf{Figure 1}
Trial profile. ARPQ: artemisinin-piperaquine; ASAQ: artesunate-amodiaquine